Cargando…
HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia
Achieving a deep molecular response (DMR) to tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia (CML) remains challenging and at present, there is no biomarker to predict DMR in this setting. Herein, we report that an HMGCLL1 genetic variant located in 6p12.1 can be used as a predi...
Autores principales: | Park, Jong-Ho, Woo, Young Min, Youm, Emilia Moonkyung, Hamad, Nada, Won, Hong-Hee, Naka, Kazuhito, Park, Eun-Ju, Park, June-Hee, Kim, Hee-Jin, Kim, Sun-Hee, Kim, Hyeoung-Joon, Ahn, Jae Sook, Sohn, Sang Kyun, Moon, Joon Ho, Jung, Chul Won, Park, Silvia, Lipton, Jeffrey H., Kimura, Shinya, Kim, Jong-Won, Kim, Dennis (Dong Hwan) |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756062/ https://www.ncbi.nlm.nih.gov/pubmed/30555164 http://dx.doi.org/10.1038/s41375-018-0321-8 |
Ejemplares similares
-
Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia
por: Zheng, Qiaoli, et al.
Publicado: (2016) -
Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD
por: Baek, Dong Won, et al.
Publicado: (2022) -
Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors
por: Jang, Hyeok-Jae, et al.
Publicado: (2021) -
The First Korean Family With Hereditary Gelsolin Amyloidosis Caused by p.D214Y Mutation in the GSN Gene
por: Park, Kyoung-Jin, et al.
Publicado: (2016) -
5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia
por: Ahn, Jae-Sook, et al.
Publicado: (2016)